09926.HK
Akeso, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 101.20
+11.45%Year over year
Reported trailing growth
- Revenue
- -5.1%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +16.4%
- EBITDA
- +122.8%
- EPS
- +98.2%
Three-year CAGR
- Revenue
- +52.6%
- EBITDA
- -9.6%
- EBIT
- -61.0%
- Net income
- —
- EPS
- -100.0%
- Free cash flow
- -64.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026